Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib

被引：1
|
作者：
Rosenberg, J. A.
Derreumaux, D.
Gore, L.
Kearns, P.
Baruchel, A.
Barrett, T.
Zwaan, M.
机构：
[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[3] Univ Colorado Denver, Aurora, CO USA
[4] Childrens Hosp, Aurora, CO USA
[5] Univ Birmingham, Birmingham, W Midlands, England
[6] Hop St Louis, Paris, France
[7] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS281
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to imatinib.
    Zwaan, Michel
    Stork, Linda C.
    Bertrand, Yves
    Gore, Lia
    Hijiya, Nobuko
    De Souza, Carmino
    Lee, Maria Lucia de Martino
    Bradley-Garelik, M. Brigid
    Kearns, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant philadelphia-positive (Ph plus) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP)
    Jabbour, Elias
    Hochhaus, Andreas
    le Coutre, Philipp
    Baccarani, Michele
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Gattennann, Norbert
    Haque, Ari
    Gallagher, Neil
    Giles, Francis
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 315A - 315A
  • [3] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or-intolerant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia
    Giles, F.
    Le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Haque, A.
    Shou, Y.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 206 - 207
  • [5] Efficacy of dasatinib (SPRYCEL®) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib:: Updated results of the CA180013 'START C' phase II study.
    Baccarani, Michele
    Kantarjian, H. M.
    Apperley, J. F.
    Lipton, J. H.
    Druker, B.
    Countouriotis, A.
    Ezzeddine, R.
    Hochhaus, A.
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [6] A phase II study of nilotinib,a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in chronic phase
    Martinelli, G.
    Rosti, G.
    Le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gatterman, N.
    Haque, A.
    Resta, D.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 207 - 207
  • [7] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Imatinib in children with newly diagnosed chronic phase chronic myelogenous leukemia (CP CML): AAML0123 COG study.
    Champagne, Martin A.
    Fu, Cecilia
    Chang, Myron
    Cooley, Linda
    Heerema, Nyla A.
    Wood, Charlotte
    French, Mary Ellen
    Smith, Franklin O.
    Bernstein, Mark L.
    BLOOD, 2006, 108 (11) : 607A - 607A
  • [9] Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
    Hazarika, Maitreyee
    Jiang, Xiaoping
    Liu, Qi
    Lee, Shwu-Luan
    Ramchandani, Roshni
    Garnett, Christine
    Orr, Micheal S.
    Sridhara, Rajeshwari
    Booth, Brian
    Leighton, John K.
    Timmer, William
    Harapanhalli, Ravi
    Dagher, Ramzi
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2008, 14 (17) : 5325 - 5331
  • [10] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
12345